

UPN4282.ST25.txt  
SEQUENCE LISTING

<110> The Trustees of The University of Pennsylvania  
Lambris, John D.

<120> COMPSTATIN ANALOGS WITH IMPROVED ACTIVITY

<130> UPN-4282

<140>

<141> 2003-09-22

<150> US 60/412,220

<151> 2002-09-20

<160> 15

<170> PatentIn version 3.2

<210> 1

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic Construct

<220>

<221> MISC\_FEATURE

<222> (13)..(13)

<223> COOH terminus of Thr is replaced by CONH2

<400> 1

Ile Cys Val Val Gln Asp Trp Gly His His Arg Cys Thr  
1 5 10

<210> 2

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic Construct

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> Ile is acetylated

<220>

<221> MISC\_FEATURE

<222> (13)..(13)

<223> COOH terminus of Thr is replaced by CONH2

<400> 2

Ile Cys Val Val Gln Asp Trp Gly His His Arg Cys Thr  
1 5 10

<210> 3

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

UPN4282.ST25.txt

&lt;223&gt; Synthetic Construct

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (1)..(1)

&lt;223&gt; Ile is acetylated

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (13)..(13)

&lt;223&gt; COOH terminus of Thr is replaced by CONH2

&lt;400&gt; 3

Ile Cys Val Tyr Gln Asp Trp Gly Ala His Arg Cys Thr  
1 5 10

&lt;210&gt; 4

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic Construct

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (1)..(1)

&lt;223&gt; Ile is acetylated

&lt;400&gt; 4

Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr  
1 5 10

&lt;210&gt; 5

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic Construct

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (1)..(1)

&lt;223&gt; Ile is acetylated

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (13)..(13)

&lt;223&gt; COOH terminus of Thr is replaced by CONH2

&lt;400&gt; 5

Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr  
1 5 10

&lt;210&gt; 6

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

UPN4282.ST25.txt

&lt;223&gt; Synthetic Construct

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (1)..(1)

&lt;223&gt; Ile is acetylated

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (13)..(13)

&lt;223&gt; Xaa is D-Thr instead of L-Thr

&lt;400&gt; 6

Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Xaa  
1 5 10

&lt;210&gt; 7

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic Construct

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (1)..(1)

&lt;223&gt; Ile is acetylated

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (4)..(4)

&lt;223&gt; Xaa is 2-naphthylalanine

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (13)..(13)

&lt;223&gt; COOH terminus of Thr is replaced by CONH2

&lt;400&gt; 7

Ile Cys Val Xaa Gln Asp Trp Gly Ala His Arg Cys Thr  
1 5 10

&lt;210&gt; 8

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic Construct

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (1)..(1)

&lt;223&gt; Ile is acetylated

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (4)..(4)

&lt;223&gt; Xaa is 2-naphthylalanine

&lt;400&gt; 8

UPN4282.ST25.txt

Ile Cys Val Xaa Gln Asp Trp Gly Ala His Arg Cys Thr  
1 5 10

<210> 9  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic Construct

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> Ile is acetylated

<220>  
<221> MISC\_FEATURE  
<222> (4)..(4)  
<223> Xaa is 1-naphthylalanine

<400> 9

Ile Cys Val Xaa Gln Asp Trp Gly Ala His Arg Cys Thr  
1 5 10

<210> 10  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic Construct

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> Ile is acetylated

<220>  
<221> MISC\_FEATURE  
<222> (4)..(4)  
<223> Xaa is 2-indanylglycine carboxylic acid

<220>  
<221> MISC\_FEATURE  
<222> (13)..(13)  
<223> COOH terminus of Thr is replaced by CONH2

<400> 10

Ile Cys Val Xaa Gln Asp Trp Gly Ala His Arg Cys Thr  
1 5 10

<210> 11  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic Construct

<220>  
<221> MISC\_FEATURE

UPN4282.ST25.txt

&lt;222&gt; (1)..(1)

&lt;223&gt; Ile is acetylated

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (4)..(4)

&lt;223&gt; Xaa is 2-indanylglycine carboxylic acid

&lt;400&gt; 11

Ile Cys Val Xaa Gln Asp Trp Gly Ala His Arg Cys Thr  
1 5 10

&lt;210&gt; 12

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic Construct

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (1)..(1)

&lt;223&gt; Ile is acetylated

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (4)..(4)

&lt;223&gt; Xaa is dihydrotryptophan

&lt;400&gt; 12

Ile Cys Val Xaa Gln Asp Trp Gly Ala His Arg Cys Thr  
1 5 10

&lt;210&gt; 13

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic Construct

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (1)..(1)

&lt;223&gt; Ile is acetylated

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (4)..(4)

&lt;223&gt; Xaa is benzoylphenylalanine

&lt;400&gt; 13

Ile Cys Val Xaa Gln Asp Trp Gly Ala His Arg Cys Thr  
1 5 10

&lt;210&gt; 14

&lt;211&gt; 16

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

UPN4282.ST25.txt

&lt;223&gt; Synthetic Construct

&lt;400&gt; 14

Gly Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr Ala Asn  
1 5 10 15

&lt;210&gt; 15

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic Construct

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (1)..(1)

<223> Xaa is Ile, Val, Leu, acetylated Ile, acetylated Val, acetylated  
Leu, or dipeptide Gly-Ile

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (4)..(4)

&lt;223&gt; Xaa is Trp or a peptidic or non-peptidic Trp analog

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (9)..(9)

&lt;223&gt; Xaa is His, Ala, Phe or Trp

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (13)..(13)

<223> Xaa is L-Thr, D-Thr, Ile, Val, Gly or a tripeptide comprising  
Thr-Ala-Asn, and the terminal COOH of the terminal residue  
optionally is replaced by CONH2

&lt;400&gt; 15

Xaa Cys Val Xaa Gln Asp Trp Gly Xaa His Arg Cys Xaa  
1 5 10